Deborah L Keller
CIK 1352992 · CEO, Covance Drug Development · last filed 2026-05-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.36M
Companies
3
Total Filings
41
Lifetime Open-Market Net
-$5.91M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Recent Filings · Page 4 of 5
41 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2011-02-22 | COVANCE INC (CVD) Delisted | Mixed | +21,771 | -$4.5K | EDGAR |
| 2010-12-21 | COVANCE INC (CVD) Delisted | Tax (F) | −766 | $0 | EDGAR |
| 2010-06-24 | COVANCE INC (CVD) Delisted | Disc (I) | −956 | -$52.0K | EDGAR |
| 2010-02-18 | COVANCE INC (CVD) Delisted | Mixed | +2,206 | $0 | EDGAR |
| 2009-12-21 | COVANCE INC (CVD) Delisted | Tax (F) | −2,272 | -$116.3K | EDGAR |
| 2009-02-23 | COVANCE INC (CVD) Delisted | Mixed | +5,621 | -$12.6K | EDGAR |
| 2008-12-22 | COVANCE INC (CVD) Delisted | Tax (F) | −3,473 | -$142.4K | EDGAR |
| 2008-09-02 | COVANCE INC (CVD) Delisted | Mixed | — | -$195.2K | EDGAR |
| 2008-02-22 | COVANCE INC (CVD) Delisted | Grant (A) | +4,672 | $0 | EDGAR |
| 2007-09-11 | COVANCE INC (CVD) Delisted | Mixed | — | -$157.2K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.